UroGen Pharma (NASDAQ:URGN) Given “Buy” Rating at HC Wainwright

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They currently have a $54.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 279.21% from the stock’s current price.

Separately, Oppenheimer dropped their price target on shares of UroGen Pharma from $35.00 to $34.00 and set an “outperform” rating on the stock in a research note on Friday, March 15th.

UroGen Pharma Trading Down 1.7 %

NASDAQ URGN opened at $14.24 on Thursday. UroGen Pharma has a 1-year low of $8.69 and a 1-year high of $24.13. The company has a market capitalization of $333.93 million, a PE ratio of -3.82 and a beta of 1.07. The firm’s fifty day simple moving average is $16.38 and its 200-day simple moving average is $14.59.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.05). The firm had revenue of $23.53 million for the quarter, compared to analyst estimates of $22.30 million. As a group, analysts predict that UroGen Pharma will post -3.59 EPS for the current year.

Insiders Place Their Bets

In other UroGen Pharma news, insider Mark Schoenberg sold 3,789 shares of the stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $15.74, for a total transaction of $59,638.86. Following the transaction, the insider now directly owns 149,423 shares of the company’s stock, valued at $2,351,918.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, General Counsel Jason Drew Smith sold 4,993 shares of UroGen Pharma stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $15.74, for a total value of $78,589.82. Following the transaction, the general counsel now directly owns 18,824 shares in the company, valued at $296,289.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mark Schoenberg sold 3,789 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $15.74, for a total value of $59,638.86. Following the completion of the sale, the insider now directly owns 149,423 shares in the company, valued at approximately $2,351,918.02. The disclosure for this sale can be found here. Insiders have sold 20,782 shares of company stock valued at $306,829 over the last three months. 11.13% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. RTW Investments LP increased its position in UroGen Pharma by 101.4% in the 4th quarter. RTW Investments LP now owns 1,726,808 shares of the company’s stock worth $25,902,000 after buying an additional 869,344 shares during the period. RA Capital Management L.P. bought a new position in UroGen Pharma in the 3rd quarter worth approximately $20,787,000. Stonepine Capital Management LLC increased its position in UroGen Pharma by 16.1% in the 4th quarter. Stonepine Capital Management LLC now owns 1,304,947 shares of the company’s stock worth $11,575,000 after buying an additional 180,727 shares during the period. BlackRock Inc. increased its position in UroGen Pharma by 285.9% in the 2nd quarter. BlackRock Inc. now owns 1,097,916 shares of the company’s stock worth $11,363,000 after buying an additional 813,377 shares during the period. Finally, Millennium Management LLC increased its position in UroGen Pharma by 292.8% in the 2nd quarter. Millennium Management LLC now owns 616,245 shares of the company’s stock worth $5,047,000 after buying an additional 459,341 shares during the period. 91.29% of the stock is owned by institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.